LiPlasome Pharma ApS

LiPlasome is a Danish privately owned biotech company focusing on oncology.

The LiPlasome technology provides a liplasomal reformulation of the most used anticancer drugs on the market like Cispaltin -> LiPlaCis® and Oxaliplatin -> LiPloxa.

The aim is to provide more effective treatment to cancer patients with fewer side effects.

LiPlasomes most advanced program I LiPlaCis® in a close escalating clinical phase I trial. In addition one programme is in pre-clinical development.

LiPlasome Pharma ApS
Diplomvej 378
DK-2800 Lyngby

CEO
Peter Buhl Jensen
pbj@liplasome.com
Phone: +45 216 089 22

COO
Mogens Winkel Madsen
mwm@liplasome.com
Phone: +45 268 014 21

 

Link to Liplasome Teamsite